Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7066 to 7080 of 8225 results

  1. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued Reference number: GID-TA10028

    Technology appraisal guidance
    Discontinued

  2. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued Reference number: GID-TA10033

    Technology appraisal guidance
    Discontinued

  3. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued Reference number: GID-TA10045

    Technology appraisal guidance
    Discontinued

  4. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued Reference number: GID-TA10047

    Technology appraisal guidance
    Discontinued

  5. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued Reference number: GID-TA10065

    Technology appraisal guidance
    Discontinued

  6. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

    Technology appraisal guidance
    Discontinued

  7. Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

    Discontinued Reference number: GID-TA10070

    Technology appraisal guidance
    Discontinued

  8. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued Reference number: GID-TA10074

    Technology appraisal guidance
    Discontinued

  9. Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

    Discontinued Reference number: GID-TA10081

    Technology appraisal guidance
    Discontinued

  10. Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

    Discontinued Reference number: GID-TA10087

    Technology appraisal guidance
    Discontinued

  11. Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

    Discontinued Reference number: GID-TA10088

    Technology appraisal guidance
    Discontinued

  12. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued Reference number: GID-TA10099

    Technology appraisal guidance
    Discontinued

  13. Personal, social, health and economic education focusing on sex and relationships and alcohol education

    Discontinued Reference number: GID-PHG0

    NICE guideline
    Discontinued

  14. Maternal health: promoting maternal health through community based strategies

    Discontinued Reference number: GID-QS10016

    Quality standard
    Discontinued

  15. Seven day working

    Discontinued Reference number: GID-QS10108

    Quality standard
    Discontinued